Page 187 - Genentech News Today

Biotech drug manufacturer Genentech announced it is closing its South San Francisco production facility.

MAINZ, Germany, March 28, 2023 -- BioNTech SE  today announced that it has entered into a new share repurchase program , pursuant to which the Company may purchase American Depositary Shares,... | March 28, 2023

MAINZ, Germany, March 28, 2023(Nasdaq: BNTX, "BioNTech" or the "Company") today announced that it has entered into a new share repurchase program (the "Program"), pursuant to which the Company may purchase

The history of biotechnology shows how humans have been manipulating nature for our benefit for a long time—and how modern genetic engineering is

/PRNewswire/ -- The Healthcare Businesswomens Association (HBA) has appointed Mary Stutts as Chief Executive Officer where she will lead the global...

The extra-respiratory symptoms of aspirin-exacerbated respiratory disease improved with omalizumab at baseline and during aspirin challenges, according to a study published in The Journal of Allergy & Clinical Immunology. This treatment may enable patients to reduce or eliminate their use of corticosteroids in treating these symptoms, Hiroaki Hayashi, MD, PhD, Clinical Research Center for

Many companies hope to make bioprocessing greener. One example described here nearly two years ago was Genentech’s increasing use of recycling and sustainable energy. Beyond recycling, bioprocessors might reuse waste. More than powering Doc Brown’s DeLorean in Back to the Future, banana peels, for example, could fuel the manufacturing of some biopharmaceuticals.

Mary Stutts Becomes HBAs First Woman of Color CEO Incoming HBA CEO Prioritizes Preparing Women for C-Suite and Corporate Board Roles and Advancin...

Operator: Good day, ladies and gentlemen. Thank you for standing by. Welcome to todays Full Year and Fourth Quarter Earnings and Business Update Conference Call by Affimed N.V.

Overall treatment outcomes among patients with extensive-stage small cell lung cancer who received first-line chemoimmunotherapy appeared comparable to those reported in pivotal clinical trials, according to study results.However, outcomes after chemoimmunotherapy may differ between those who meet eligibility criteria for pivotal clinical trials and those who do not, researchers concluded.